Asked by: Gill Furniss (Labour - Sheffield, Brightside and Hillsborough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of including material on (a) diagnosing and (b) detecting cardiovascular diseases in women's health hubs.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: David Davis (Conservative - Haltemprice and Howden)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what her planned timescale is for ambulance service data to be active on the Federated Data Platform for use by participating hospital trusts.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate she has made of the amount of funding allocated to the research of Parkinson's disease over the next five years.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Research (NIHR) welcomes funding applications for research into any aspect of human health, including Parkinson’s disease. Future funding allocated to research into Parkinson’s disease, and into other aspects of human health, will depend on the volume and quality of proposals received from the research community, with the level of spending outlined in the end of year accounting.
The Department, through the NIHR, invested £12.2 million into Parkinson’s research over five financial years, ending in 2022/23. The NIHR has supported a broad portfolio of Parkinson’s research and, in the last year alone, supported the conduct of 114 studies relating to Parkinson’s disease through the NIHR Clinical Research Network. For example, the NIHR is investing £3 million in the PD MED clinical trial, which investigates the efficacy of different drugs in the treatment of Parkinson’s disease. The usual practice of the NIHR is not to ring-fence funds for expenditure on particular topics.
Asked by: Baroness Bennett of Manor Castle (Green Party - Life peer)
Question to the Department for Environment, Food and Rural Affairs:
To ask His Majesty's Government what assessment they have made of the risk of H5N1 bird flu, following an outbreak in cattle in multiple US states with reports that many cattle are asymptomatic; what monitoring they carry out on (1) cattle, (2) other farm animals, (3) wild mammals, and (4) humans in contact with cattle; and what, if any, additional biosecurity measures are planned or being developed.
Answered by Lord Douglas-Miller - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
The Government is in close contact with counterparts in the United States on the incidents of influenza of avian origin in cattle in the USA. We know that the strain of virus involved has not been detected in the UK.
Defra is working closely with the Department of Health and Social Care (DHSC), the UK Health Security Agency (UKHSA), the Food Standards Agency, the Cabinet Office and with international partners on risk assessments to consider the routes of incursion, animal to animal spread and animal to human spill-over and to review our well-tested surveillance mechanisms and preparedness activities in light of this emerging situation.
In response to the unprecedented global outbreaks of highly pathogenic avian influenza (HPAI) H5N1 in wild and kept birds, the UK's avian influenza national reference laboratory at the Animal and Plant Health Agency Weybridge laboratory has increased its surveillance in both wild birds and wild mammals and genome analysis of the virus itself while keeping a close eye on its spread in global populations of wildlife. In addition, we have published an ‘Influenza A (H5N1) infection in mammals: suspect case definition and diagnostic testing criteria’ on gov.uk to support veterinary professionals and others in knowing when to report suspicion. This case definition will be updated in due course as further information on the emerging situation in cattle in the USA becomes available.
We are monitoring the situation closely but at this time have no reason to suspect the virus is circulating in our cattle, nor is this strain of the virus circulating in Europe. We have had no recent cases of avian influenza in kept birds, or findings of influenza of avian origin in kept or wild mammals, and the risk level from wild birds is low. We have discussed the need for surveillance in wildlife, domestic animals and humans with DHSC and UKHSA and are considering the case for additional surveillance for influenza of avian origin in cattle and how best such animal health surveillance could be undertaken.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to educate current drug users on the risks of synthetic drugs.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is actively monitoring, and responding to, the continued threat posed by the growing levels of potent synthetic opioids in the United Kingdom. We are working to increase awareness of the dangers of synthetic opioids. The Government’s drug information and advice service, Talk to FRANK, aims to reduce drug misuse and its harms by increasing awareness among young people and parents. Information on synthetic opioids and the danger of their misuse is available at the following link:
https://www.talktofrank.com/drug/synthetic-opioids
Education on drug use is also a statutory component of relationships and sex education and health education in England. The Office for Health Improvement and Disparities and the Department for Education have commissioned lesson plans and other resources to support teachers in delivering quality drug prevention interventions. The lesson plans target primary and secondary students, teaching them how to manage influences and pressure, and keep themselves healthy and safe. These resources are being updated, and will have an increased emphasis on the risks of synthetic drugs.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to prevent increased synthetic drug use.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is actively monitoring, and responding to, the continued threat posed by the growing levels of potent synthetic opioids in the United Kingdom. We are working to increase awareness of the dangers of synthetic opioids. The Government’s drug information and advice service, Talk to FRANK, aims to reduce drug misuse and its harms by increasing awareness among young people and parents. Information on synthetic opioids and the danger of their misuse is available at the following link:
https://www.talktofrank.com/drug/synthetic-opioids
Education on drug use is also a statutory component of relationships and sex education and health education in England. The Office for Health Improvement and Disparities and the Department for Education have commissioned lesson plans and other resources to support teachers in delivering quality drug prevention interventions. The lesson plans target primary and secondary students, teaching them how to manage influences and pressure, and keep themselves healthy and safe. These resources are being updated, and will have an increased emphasis on the risks of synthetic drugs.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions she has had with community pharmacists on supporting people with (a) smoking and (b) vaping (i) addiction and (ii) dependency.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Quitting smoking is the best thing a smoker can do for their health and smokers are three times as likely to succeed with stop smoking services (SSS) when compared to an unsupported quit attempt. As announced in Stopping the start: our new plan to create a smokefree generation, published in October 2023, the Government is investing an additional £70 million per year for five years to support local authority-led SSS, around doubling current spend and supporting 360,000 people to set a quit date each year. Local authorities commission a variety of settings, including community pharmacy, to deliver SSS. In 2022/23, 12,165 of the 176,566 quit dates set through SSS were in a pharmacy setting. Since March 2022, hospitals have been referring patients to community pharmacy to continue the stop smoking journey they started in hospital as part of the NHS Smoking Cessation Service in community pharmacies agreed by the Department, NHS England and Community Pharmacy England. Across the country, 4841 community pharmacies have signed up to deliver the service.
In addition, we are establishing a financial incentives scheme to help pregnant smokers and their partners to quit smoking, with smoking cessation support. This evidence-based intervention will encourage pregnant women to give up smoking, and remain smokefree throughout pregnancy and beyond, helping to improve the health and wellbeing of both mother and baby.
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the policy paper entitled People at the Heart of Care, published by her Department in December 2021, CP 560, what steps her Department has taken to raise awareness of Carer's Leave amongst unpaid carers.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
The Government is committed to supporting unpaid carers to balance their caring alongside work, and to do so in a way that supports their own health and wellbeing.
As indicated in People at the Heart of Care in 2021, the Department for Business and Trade (DBT) are the lead department for carer’s leave. DBT has carried out a range of activities to raise awareness of Carer’s Leave, including producing associated guidance available through GOV.UK, working closely stakeholders such as carer and business representative organisations and promoting Carers Leave through the ‘Help to Grow’ website.
The Department for Health and Social Care continues to seek and use opportunities to raise awareness of support services and relevant legislation, including carer’s leave, amongst unpaid carers. This includes through our ongoing engagement with carer representative organisations, the use of GOV.UK and engagement in events such as during Carers Week, which this year takes place in June 2024.
Asked by: Stephen Morgan (Labour - Portsmouth South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking ensure Integrated Care Schemes are able to support staff retention schemes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The NHS Long Term Workforce Plan sets out how to improve culture and leadership, to ensure that up to 130,000 fewer staff leave the National Health Service over the next 15 years. Key to this is the National Retention Programme. The programme builds on the NHS People Promise, and supports integrated care systems (ICSs), regions, NHS trusts, and organisations to improve employee experience to retain their people, and therefore reduce NHS staff leaver rates.
The National Retention Programme provides a suite of evidence-based, targeted, organisational-level interventions, to improve staff engagement and experience, in line with the NHS People Promise. The programme builds on the fundamentals that every organisation should be developing to support a good working environment, providing practical advice and support. It targets activities at the key career points at which staff are most likely to leave, to help improve retention.
Support for organisations and ICSs can be accessed via the Retention Hub, which outlines initiatives mapped against the NHS People Promise, access to tools, guides, and case studies, to enable improvements and contact details for regional colleagues support the retention agenda in each of the seven regions. Further information on the Retention Hub is available at the following link:
https://www.england.nhs.uk/looking-after-our-people/the-programme-and-resources/
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much the administration of the Vaccine Damage Payment Scheme cost the NHS Business Services Authority in (a) 2021, (b) 2022 and (c) 2023.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The NHS Business Services Authority (NHSBSA) administers the Vaccine Damage Payment Scheme, on behalf of the Department. Administration costs for the scheme were £600,000, £8.8 million, and £16.1 million for April 2021 to March 2022, April 2022 to March 2023, and April 2023 to March 2024, respectively. Payments made by the NHSBSA for the provision of medical records totalled £1,200, £72,000, and £73,100, for the same periods. The figures are provided to the nearest decimal place.